---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-006487"
form_type: "8-K"
ticker: "PTPI"
cik: "0001815903"
company_name: "Petros Pharmaceuticals, Inc."
filed_at: "2022-01-21T23:59:59+00:00"
generated_at: "2026-06-27T16:35:33.975659+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Petros subsidiary settles VIVUS disputes, issues $10.2M promissory note at 6% through 2027

## Summary
- Metuchen settles with VIVUS, forgives $9.6M in liabilities and retains ~$7.3M of API inventory.
- Issues $10,201,758 promissory note at 6% interest, payable quarterly from Apr 2022 to Jan 2027.
- License amended: VIVUS gets co-exclusive rights to Stendra but forbears from exercising unless default.
- Metuchen must pay $900k toward note and $1.54M for 2021 purchase order to release inventory.
- VIVUS granted right of first refusal on future debt/convertible equity financings until note paid in full.

## SEC filing metadata
- accession: 0001104659-22-006487
- form_type: 8-K
- ticker: PTPI
- cik: 0001815903
- company_name: Petros Pharmaceuticals, Inc.
- filed_at: 2022-01-21T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 1.01, 2.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1815903/000110465922006487/0001104659-22-006487-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1815903/000110465922006487/tm223291d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-006487
- JSON: https://secwatch.observer/filing/0001104659-22-006487.json
- Plain text: https://secwatch.observer/filing/0001104659-22-006487.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.